

RESEARCH

Open Access

# Human mesenchymal stem cells possess different biological characteristics but do not change their therapeutic potential when cultured in serum free medium

Youwei Wang<sup>1,2,3†</sup>, Hehe Wu<sup>1†</sup>, Zhouxin Yang<sup>1</sup>, Ying Chi<sup>1</sup>, Lei Meng<sup>2,3</sup>, Aibin Mao<sup>2</sup>, Shulin Yan<sup>2</sup>, Shanshan Hu<sup>2</sup>, Jianzhong Zhang<sup>2</sup>, Yun Zhang<sup>2</sup>, Wenbo Yu<sup>2</sup>, Yue Ma<sup>2</sup>, Tao Li<sup>2</sup>, Yan Cheng<sup>2</sup>, Yongjuan Wang<sup>2</sup>, Shanshan Wang<sup>2</sup>, Jing Liu<sup>2</sup>, Jingwen Han<sup>2</sup>, Caiyun Li<sup>2</sup>, Li Liu<sup>2</sup>, Jian Xu<sup>2</sup>, Zhi Bo Han<sup>1,2,3\*</sup> and Zhong Chao Han<sup>1,2,3\*</sup>

## Abstract

**Introduction:** Mesenchymal stem cells (MSCs) are widely investigated in clinical researches to treat various diseases. Classic culture medium for MSCs, even for clinical use, contains fetal bovine serum. The serum-containing medium (SCM) seems a major obstacle for MSCs-related therapies due to the risk of contamination of infectious pathogens. Some studies showed that MSCs could be expanded in serum free medium (SFM); however, whether SFM would change the biological characteristics and safety issues of MSCs has not been well answered.

**Methods:** Human umbilical cord mesenchymal stem cells (hUC-MSCs) were cultured in a chemical defined serum free medium. Growth, multipotency, surface antigen expression, telomerase, immunosuppressive ability, gene expression profile and genomic stability of hUC-MSCs cultured in SFM and SCM were analyzed and compared side by side.

**Results:** hUC-MSCs propagated more slowly and senesce ultimately in SFM. SFM-expanded hUC-MSCs were different from SCM-expanded hUC-MSCs in growth rate, telomerase, gene expression profile. However, SFM-expanded hUC-MSCs maintained multipotency and the profile of surface antigen which were used to define human MSCs. Both SFM- and SCM-expanded hUC-MSCs gained copy number variation (CNV) in long-term *in vitro* culture.

**Conclusion:** hUC-MSCs could be expanded in SFM safely to obtain enough cells for clinical application, meeting the basic criteria for human mesenchymal stem cells. hUC-MSCs cultured in SFM were distinct from hUC-MSCs cultured in SCM, yet they remained therapeutic potentials for future regenerative medicine.

## Introduction

Mesenchymal stem cells (MSCs) possess the ability of self-renew and multipotency. These cells can replicate *in vitro* and have the potential to differentiate to bone, fat and cartilage tissues [1]. Numerous preclinical and clinical studies have demonstrated that MSCs hold an alluring prospect as cellular therapies, based on their

multipotency, hematopoietic-supporting and immunosuppressive abilities. MSC-based tissue-engineering approaches could treat patients with long bone defects [2,3]. Co-transplantation of MSCs with HLA-disparate hematopoietic stem cells could accelerate lymphocyte recovery and reduce the risk of graft failure [4]. For the small effect on T-cell responses to pathogens, infusion of MSCs suppressed alloantigen-induced T-cell function and might be a promising therapy for graft-versus-host disease [5,6]. MSCs, described as a very rare population in bone marrow by Friedenstein and colleagues [7], need to be expanded *in vitro* to achieve the amount required for administration. Several safety-related issues have

\* Correspondence: zhibohan@163.com; hanzhongchao@hotmail.com

†Equal contributors

<sup>1</sup>State Key Laboratory of Experimental Hematology, National Engineering Research Center of Stem Cells, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Science & Peking Union Medical College, 288 Nanjing Road, 300020 Tianjin, China

Full list of author information is available at the end of the article

been of wide concern in clinical applications of *in vitro* expanded MSCs. It is not clear whether MSCs could maintain genomic stability during expansion *in vitro* and whether injection of MSCs could lead to cancer *in vivo*.

Many studies have demonstrated that MSCs will not undergo malignant transformation after long-term *in vitro* culture in serum-containing culture [8]. Other studies on pluripotent stem cells have revealed that the number of chromosomes and the copy number of specific regions in the genome of embryonic stem cells or induced pluripotent stem cells could mutate in the process of *in vitro* expansion [9-14]. Similarly, copy number variation (CNV) was found in adipose tissue-derived MSCs [15] after long-term culture, even though they did not undergo malignant transformation. Previous studies paid much attention to the safety issues of MSCs cultured in serum-containing medium (SCM) [16]. However, it is not desirable to prepare MSCs for clinical application in SCM. The utmost problem associated with bovine and human serum is the safety issue. Bovine serum might contain zoonotic viruses (including prion), which cannot be cleaned up during the process of preparing MSCs for clinical use. Human serum might contain undetectable pathogen, which could easily spread between human beings during stem cell transplantation. From this perspective, human serum is more dangerous than serum of animals. In recent years, some human serum or human platelet lysate products are solvent/detergent treated, which makes them much less likely to transmit an infectious disease, without deleting the risk completely [17].

In addition, serum is ill-defined, has a high degree of batch-to-batch variation, is hard to standardize and can harm the process control and stability of quality and production. Serum-free medium (SFM) is an ideal system for cellular therapy. MSCs expanded in SFM perform much better in quality control and stability. Many previous studies focused on increasing attachment and growth of MSCs in SFM [18]. Other studies evaluated the clinical application related biological characteristics of SFM-expanded MSCs [19,20]. However, the safety and efficacy of MSCs cultured in SFM have not been well evaluated [21]. In this study we investigated whether human umbilical cord mesenchymal stem cells (hUC-MSCs) expanded in SFM change their biological characteristics and clinical safety-related issues, which included genome and transcriptome stability.

## Methods

### Growth characteristics of MSCs in serum-free medium

hUC-MSCs derived from five different donors were isolated from Wharton's jelly by enzymatic digestion [22] and frozen in a master cell bank after short-term expansion in SCM. This study is approved by the Institutional Review Board of the Chinese Academy of Medical Science and

Peking Union Medical College. Umbilical cords were obtained following the ethical guidelines with written informed consent from donors. All experimental research of this study was in compliance with the Helsinki Declaration. After recovery from the master cell bank, hUC-MSCs were cultured on a tissue culture surface with SCM that contained 10% fetal bovine serum (ExCell Bio, Shanghai, China) or on a chemically treated cell culture surface (CellBIND; Corning Incorporated, Corning, NY, USA) with a chemically defined SFM (MSCGM-CD; Lonza, Walkersville, MD, USA), at 37°C and 5% carbon dioxide. After reaching 90% confluence, hUC-MSCs were detached and subcultured at a ratio of 1:3 until reaching senescence. The time needed to obtain confluence for every passage was recorded to calculate the population-doubling time.  $\beta$ -galactosidase were analyzed at late passage by a cellular senescence assay kit (Millipore, Billerica, MA, USA) following the manufacturer's protocol. In this assay, senescent cells were stained as a distinctive blue color.

### Differentiation of MSCs cultured in serum-free medium

For osteogenic and adipogenic differentiation, SFM-expanded hUC-MSCs at the 10th passage were seeded in 24-well plates at a concentration of  $5 \times 10^4$  cells per well. The StemPro Adipogenesis Differentiation Kit (A10070-01; GIBCO, Grand Island, NY, USA) and the Osteogenesis Differentiation Kit (A10072-01; GIBCO) were used as the differentiation-inducing medium. The medium was refreshed twice every week. After 21 days of differentiation, cells were fixed in 70% ethanol and stained with Alizarin Red S (for osteogenic differentiation) or Oil Red O (for adipogenic differentiation). For chondrogenic differentiation,  $4 \times 10^5$  SFM-expanded hUC-MSCs at the 10th passage were suspended in 1 ml StemPro Chondrogenesis Differentiation Kit (A10071-01; GIBCO) and distributed to 15 ml centrifuge tubes. Cells were centrifuged at  $500 \times g$  for 5 minutes and then placed in an incubator with the caps loosened. The chondrogenic culture was refreshed twice every week. After 21 days of chondrogenesis, the pellets were fixed in 4% formaldehyde, cut to 5  $\mu$ m and stained by Toluidine blue.

### Flow cytometric analysis

hUC-MSCs expanded in SFM at the 10th passage were characterized by flow cytometric analysis for specific antigens. For the analysis of cell surface markers, hUC-MSCs expanded in SFM were harvested after detachment, washed in phosphate-buffered saline and then incubated with phycoerythrin-labeled or fluorescein isothiocyanate-labeled monoclonal antibodies against CD14 (12-0149-42; eBioscience, San Diego, CA, USA), CD19 (555413; BD Biosciences, Franklin Lakes, NJ, USA), CD34 (555821; BD Biosciences), CD45 (103105; BioLegend, San Diego, CA, USA), CD73 (550257; BD Biosciences), CD90 (555596; BD

Biosciences), CD105 (560839; BD Biosciences), HLA-ABC (555552; BD Biosciences) and HLA-DR (555812; BD Biosciences). For analyzing the expression of Nestin, which is an intracellular marker, SFM-expanded hUC-MSCs were fixed and permeabilized by the Cytofix/Cytoperm™ Fixation/Permeabilization Kit (554714; BD Biosciences). The cells were then stained by phycoerythrin-conjugated antibodies against Nestin. CellQuest was used to perform the analysis on FACS Calibur' (BD Biosciences, San Jose, CA, USA).

#### Telomerase reverse transcriptase analysis

RNA was extracted from SCM-expanded and SFM-expanded hUC-MSCs in SFM using the E.Z.N.A Total RNA Kit (Omega Bio-Tek, Norcross, GA, USA). cDNA was synthesized by M-MLV Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). TaqMan-based real-time quantitative PCR assay was used to analyze the expression of *hTERT* (the human telomerase catalytic subunit gene) [23]. For each PCR run, a 20 µl reaction mix was prepared with 10 µl TaqMan Gene Expression Master Mix (2×; Applied Biosystems, Warrington, UK), 1 µl of 10 µM upper primer, 1 µl of 10 µM lower primer, 1 µl of 10 µM probe, 1 µl of cDNA and 6 µl ddH<sub>2</sub>O. The reaction mixes were then placed in Applied Biosystems real-time PCR System 7300 with the following thermal cycling conditions: 50°C for 2 minutes, 95°C for 10 minutes, 55 cycles including 95°C for 15 seconds and 60°C for 1 minute. *RPLP0* was used as a reference gene. cDNA prepared from HeLa cells was used as a positive control.

#### Immunoregulation analysis

We used lymphocyte proliferation and interferon gamma (IFN $\gamma$ ) analysis, which was described by previous studies [24,25], to evaluate the immunosuppressive ability of hUC-MSCs after culture in SFM. In brief, SCM-derived and SFM-derived hUC-MSCs were irradiated (60 Gy) and then cultured in 96-well cell culture plates. Two hours later, human peripheral blood mononuclear cells (hPBMCs) were added to hUC-MSCs and cultured with PHA (Sigma, St. Louis, MO, USA) and interleukin-2 (Peprotech, Rocky Hill, NJ, USA). hPBMCs were co-cultured with hUC-MSCs for 3 days. BrdU was added 18 hours before detection. Cell proliferation was measured by BrdU incorporation assay (Roche, Mannheim, Germany). Supernatant were harvested for IFN $\gamma$  analysis (eBioscience).

#### Genetic stability of MSCs cultured in SFM and in SCM

Two pairs of samples that expanded in SFM and SCM were sent to CapitalBio Co. (Beijing, China) for array-based comparative genomic hybridization (aCGH) analysis following the protocol described on the website of CapitalBio Co. [26]. Briefly, the genomic DNA was extracted and purified from hUC-MSCs by phenol-

chloroform. According to the quality control requirements of NimbleGen (Madison, WI, USA), the genomic DNA was undegraded and has A260/A280  $\geq$  1.8 and A260/A230  $\geq$  1.9. NimbleGen human whole-genome tiling arrays containing up to 4.2 million probes, spanning the human genome with a median probe spacing of 2,509 base pairs (Human CGH 3x720K Whole-Genome Tiling v3.0 Array, 05547717001; NimbleGen), were utilized for aCGH analysis. Genomic DNA extracted from SCM-expanded or SFM-expanded hUC-MSCs at the 10th passage was labeled with Cy3. DNA isolated from hUC-MSCs at the third passage, derived from the same donors as those from whom serum-free culture or serum-containing culture were established, were labeled with Cy5 and used as reference samples.

Test (10th passage) and reference (3rd passage) samples were co-hybridized onto arrays and scanned using a MS200 scanner (NimbleGen) with 2 µm resolution. Cy3 and Cy5 signal intensities were computed and normalized using the q-spline method [27]. Segments with  $|\text{mean log}_2 \text{ ratio}| \geq 0.25$  and at least five consecutive probes were scored as aberrant DNA copy number changes.

#### Transcriptome analysis

Three pairs of hUC-MSC samples, before and after expansion in SFM, were sent to CapitalBio Co. for mRNA microarray analysis. Total RNA was extracted and then qualified by formaldehyde agarose gel electrophoresis. After being quantitated spectrophotometrically, 1 µg total RNA was used to synthesize double-stranded cDNA and then produced biotin-tagged cRNA using the MessageAmp™ II aRNA Amplification Kit (Invitrogen). According to the protocol from Affymetrix (Santa Clara, CA, USA), bio-tagged cRNA was fragmented and hybridized to Human Genome U133 Plus 2.0 containing over 47,000 transcripts. After hybridizing, the arrays were washed, stained by Affymetrix Fluidics Station 450 and scanned by GeneChip Scanner 3000. The intensity values of different microarray were normalized and log<sub>2</sub> transformed using the RMA gene core algorithm provided by the Expression Console (Affymetrix). Genes with at least twofold changes were selected for further analysis. The Molecule Annotation System (online analysis system provided by CapitalBio Co.) was used to perform Gene Ontology and pathway analysis. Microarray data were deposited into a public database [Gene Expression Omnibus:GSE62665].

#### Real-time PCR analysis

Real-time PCR was used to validate the data obtained from the mRNA microarray. Twelve differentially expressed genes including six upregulated genes and six downregulated genes were selected for validation by real-time PCR. These 12 genes included genes related to the cell cycle pathway,

histone, cytokine, *MAPK8* and *PIK3R1*. *MAPK8* and *PIK3R1* were selected because they implicated in a large number of pathways. GoTaq Green Master Mix (Promega, Madison, WI, USA) was used for real-time PCR in the 7300 real-time PCR System (Applied Biosystems). Relative expression levels were calculated using  $\Delta\Delta C_T$  method. Seven housekeeping genes were selected as the candidates of reference genes, and we used geNorm [28] for choosing the most stably expressed housekeeping genes as reference genes for data analysis.

## Results

### Growth characteristics of MSCs in serum-free medium

As shown in Figure 1a,b, hUC-MSCs maintained a fibroblastoid appearance in SFM, without noticeable morphological difference to cells expanded in SCM. The major difference between SFM-cultured and SCM-cultured hUC-MSCs was the growth rate and proliferating lifespan *in vitro*. Compared with hUC-MSCs expanded in SCM, the population-doubling time of hUC-MSCs cultured in SFM was prolonged significantly, which meant hUC-MSCs proliferated more slowly in SFM. The population-doubling time of SCM-cultured hUC-MSCs was maintained relatively constant, which was shorter than 2 days before the 20th passage (Figure 1c). The population-doubling time of SFM-cultured hUC-MSCs was very unsteady, which increased with passaging until the senescent stage.

Four out of five hUC-MSCs in this study showed a much shorter lifespan in SFM compared with that in SCM (Figure 1d). They entered the senescence phase between the 10th and 16th passages, which was equivalent to approximately 15 to 20 population doublings. Only one sample displayed a better proliferating capacity in SFM, which reached the senescence phase at the 26th passage. In SCM, all hUC-MSCs in this study did not show any senescent sign before the 30th passage (approximately 47 population doublings).

Actually, we tested at least three different commercial SFMs. In all of them, hUC-MSCs showed much slower growth rate and shorter *in vitro* lifespan compared with that in SCM (Figure 1e). This implied that SFM for MSCs still needs further modification to meet the requirements of growth support. hUC-MSCs cultured in SFM showed a progressive decrease in growth rate and ultimately achieved senescence (Figure 1f). No immortalization or malignant transformation was observed in the culture of hUC-MSCs in SFM.

### Multipotency of serum-free medium-expanded hUC-MSCs

Multipotency of SFM-expanded hUC-MSCs at the 10th passage was evaluated by osteogenic, adipogenic and chondrogenic differentiation. After 21 days of inducing culture, osteogenesis, adipogenesis and chondrogenesis were analyzed by Alizarin Red, Oil Red O and Toluidine

Blue separately. As showed in Figure 2a,b,c, SFM-expanded hUC-MSCs differentiate to osteocytes, adipocytes and chondrocytes, which indicates that hUC-MSCs maintained multipotency after *in vitro* expansion in SFM.

### Specific surface antigen expression


Flow cytometric analysis of SFM-expanded hUC-MSCs at the 10th passage is presented in Figure 2d. hUC-MSCs cultured in SFM expressed CD105, CD73, CD90 and HLA-ABC and lacked expression of CD34, CD45, CD14, CD19 and HLA-DR, which met the minimal criteria for identifying human MSCs [29]. In this study, all surface marker expression patterns of SFM-expanded hUC-MSCs were similar to those of SCM-expanded hUC-MSCs. Both SFM-expanded and SCM-expanded hUC-MSCs were positive for Nestin, which were considered to encompass features attributed to hematopoietic niche [30].


### Expression of *hTERT*

Activation or upregulation of *hTERT* is very important for malignant transformation and immortalization of normal human cells [31,32]. It is therefore necessary to analyze the expression of *hTERT* in MSCs that were cultured in SFM before clinical application. There is controversy about the expression of *hTERT* in MSCs. Based on the analysis of the telomeric-repeat amplification protocol and PCR, Bernardo and colleagues did not find any detectable telomerase in human bone marrow-derived MSCs [33]. However, in Parsch and colleagues' study, telomerase could be detected in bone marrow MSCs by the telomeric-repeat amplification protocol [34]. Using a TaqMan-based real-time PCR assay, we found that *hTERT* was expressed in hUC-MSCs cultured in SCM at a very low level (Figure 2e). Nevertheless, after culture in SFM, no signal about *hTERT* could be detected even after 55 PCR cycles (Additional file 1). Thus, we claimed that hUC-MSCs possessed expression of *hTERT*, but lost it in SFM.

### Immunosuppressive ability of serum-free medium-expanded hUC-MSCs

To study whether SFM-expanded hUC-MSCs maintained their immunosuppressive ability, we performed an *in vitro* co-culture experiment. First, we analyzed the effect of SFM-expanded hUC-MSCs on inhibiting proliferation of activated hPBMCs by BrdU incorporation assay. Our data showed that SFM-expanded hUC-MSCs could inhibit proliferation of activated hPBMCs (Figure 2f). We then measured the IFN $\gamma$  concentration in supernatant of the co-culture system by enzyme-linked immunosorbent assay. We found that IFN $\gamma$  amounts in supernatant were significantly reduced when MSCs were added (Figure 2g). Besides, there was no significant difference between SCM-expanded and SFM-expanded hUC-MSCs on inhibiting proliferation or IFN $\gamma$  secretion of activated hPBMCs.





### Array-based comparative genomic hybridization analysis of MSCs cultured in SFM and in SCM


Two pairs of hUC-MSCs (sample 2 and sample 4) at the 10th passage, propagated in SFM and SCM, were assessed by aCGH. Both of the samples showed CNV during *in vitro* culture, no matter whether in SFM or SCM. There was no huge unbalanced genome alteration in SFM-expanded or SCM-expanded hUC-MSCs (Figure 3a,b,c,d). As shown in Table 1 and marked in Figure 3f, a total of 238 CNV segments were observed in this study: 107 segments were gained and the other 131 segments were lost. The length of affected regions varies from 4 kb to 25 Mb, with an average of 154 kb. For sample 2, more CNV was found in SFM than in SCM. However, sample 4 cultured in SCM gained much more CNV than that cultured in SFM. There is therefore no significant difference between SCM-cultured and SFM-cultured MSCs on genomic stability in this study.

The loss in chr3:181315609 to 181344028, which was found in both of the SFM-derived hUC-MSCs, did

not appear in either of the SCM-expanded hUC-MSCs (Figure 3e). No annotated genes were located in this region, thus the CNV observed only in SFM-expanded hUC-MSCs might have little or no role in altering biological characteristics. Further investigation is needed to study whether the CNV observed only in SFM-expanded hUC-MSCs was implicated, directly or indirectly, in a gene expression regulatory role. Further research was also needed to identify whether the genetic mutation was a consequence of culturing in SFM. In addition, absolute values of the  $\log_2$  ratio of CNV segments observed in this study averaged 0.31, indicating that only a small subpopulation of hUC-MSCs contained these alterations. In other words, hUC-MSCs, at least cultured hUC-MSCs, were a heterogeneous population in the genome.

### Microarray analysis of mRNA in hUC-MSCs expanded in serum-free medium

hUC-MSCs from three different donors were analyzed by mRNA chip before and after expansion in SFM. Figure 4




**Figure 3** Array-based comparative genomic hybridization analysis of human umbilical cord mesenchymal stem cells expanded in serum-free medium and serum-containing medium. Huge unbalanced genome alteration was not obvious in the single-panel rainbow plot, in which each chromosome was differentiated by color. **(a)** Sample 2 in serum-free medium (SFM). **(b)** Sample 2 in serum-containing medium (SCM). **(c)** Sample 4 in SFM. **(d)** Sample 4 in SCM. **(e)** A copy number variation (CNV) segment (chr3:181315609 to 181344028), which was observed in both of the SFM-expanded human umbilical cord mesenchymal stem cells (hUC-MSCs; red arrow), was not observed in either of the SCM-expanded samples (blue arrow). **(f)** CNV identified by array-based comparative genomic hybridization in culture. Amplifications and deletions were mapped onto the human genome for four hUC-MSC clones. Each individual CNV is marked: red circle, amplification; green circle, deletion.

**Table 1 Summary of CNV observed in SFM-expanded and SCM-expanded hUC-MSCs**

Sample	Deletion		Amplification	
	Number of CNV segments	Sum of CNV length (base pairs)	Number of CNV segments	Sum of CNV length (base pairs)
Sample 4 in SFM	10	319568	11	241958
Sample 4 in SCM	50	27084926	92	7188316
Sample 2 in SFM	31	937255	19	444733
Sample 2 in SCM	16	342620	9	200333

CNV, copy number variation; hUC-MSCs, human umbilical cord mesenchymal stem cells; SCM, serum-containing medium; SFM, serum-free medium.

visualizes the differentially expressed genes and correlations between hUC-MSC samples. Six samples were divided into two groups. In the first group, we found all hUC-MSCs cultured in SFM. All hUC-MSCs expanded in SCM fell into the second group. The separation of SFM-



expanded hUC-MSCs from SCM-expanded hUC-MSCs was very distinctive.

Gene Ontology analysis of genes with differential expression revealed that cell cycle, mitosis and cell proliferation were changed significantly in SFM-expanded hUC-MSCs (Tables 2 and 3). Similarly, pathway enrichment indicated that many differentially expressed genes in SFM-expanded hUC-MSCs were involved in the cell cycle pathway (Tables 4 and 5). This is consistent with what we observed in *in vitro* culture: hUC-MSCs grow more slowly in SFM compared with growth in SCM.

We found that 34 genes in the cell cycle pathway were downregulated (Figure 5) in SFM culture. Many *cyclin* and *cyclin-dependent kinase (CDK)* genes were in the list of downregulated genes. Considering that *cyclin* and *CDK* play the role of key regulator in the cell cycle [35], the downregulation of *cyclin* and *CDK* might explain why hUC-MSCs proliferated more slowly in SFM. Besides, we also found that almost all genes in Mini-Chromosome Maintenance (MCM) complex were downregulated in SFM. MCM, as a key component of the prereplication complex, is very important for the initiation and elongation of DNA replication [36,37]. Downregulation of *MCM* might suppress the synthesis of DNA and then slow the proliferation of hUC-MSCs in SFM. Furthermore, genes encoding growth factor and their receptor, such as

**Table 2 Gene Ontology (GO) term enriched by upregulated genes after expansion in serum-free medium (top 10)**

GO term	Count
GO:0006355 regulation of transcription, DNA dependent	57
GO:0006350 transcription	45
GO:0007165 signal transduction	43
GO:0006955 immune response	42
GO:0044419 interspecies interaction between organisms	36
GO:0019882 antigen processing and presentation	30
GO:0002474 antigen processing and presentation of peptide antigen via MHC class I	30
GO:0007275 development	23
GO:0007155 cell adhesion	22
GO:0006468 protein amino acid phosphorylation	21



**Table 3 Gene Ontology (GO) term enriched by downregulated genes after expansion in serum-free medium (top 10)**

GO term	Count
GO:0007049 cell cycle	92
GO:0006355 regulation of transcription, DNA dependent	87
GO:0006350 transcription	86
GO:0007165 signal transduction	77
GO:0051301 cell division	61
GO:0007067 mitosis	55
GO:0007275 development	52
GO:0006468 protein amino acid phosphorylation	43
GO:0007155 cell adhesion	41
GO:0006260 DNA replication	38

*EGF* and *EGFR*, *VEGF* and *VEGFR*, were also downregulated in hUC-MSCs cultured in SFM. Accordingly, a decrease in growth factor and growth factor response might also suppress the growth rate of hUC-MSCs in SFM [38].

Our data also revealed that some genes (*RFC3*, *RFC4*, *RFC5*, *EXO1*, *POLE2*) involved in the mismatch repair and nucleotide excision repair pathway were downregulated in SFM-expanded hUC-MSCs. There are two possible reasons that could explain this phenomenon: instability of


**Table 4 Pathways for upregulated genes after expansion in serum-free medium (top 10)**

Pathway	Gene symbol	Count
Regulation of actin cytoskeleton	<i>ARHGEF6</i> ; <i>ARHGEF7</i> ; <i>FN1</i> ; <i>ITGA10</i> ; <i>ITGB8</i> ; <i>PDGFD</i> ; <i>PIK3R1</i> ; <i>PIK3R3</i> ; <i>SCIN</i>	9
Mitogen-activated protein kinase signaling pathway	<i>DDIT3</i> ; <i>ELK4</i> ; <i>IL1R1</i> ; <i>MAP2K5</i> ; <i>MAP2K6</i> ; <i>MAP3K5</i> ; <i>MAP3K8</i> ; <i>MKNK1</i> ; <i>PLA2G12A</i>	9
Systemic lupus erythematosus	<i>C1R</i> ; <i>C1S</i> ; <i>HIST1H2AC</i> ; <i>HIST1H2BC</i> ; <i>HIST1H2BD</i> ; <i>HIST1H2BK</i> ; <i>HIST1H4H</i>	7
Jak-STAT signaling pathway	<i>IL20RB</i> ; <i>JAK3</i> ; <i>LIFR</i> ; <i>PIK3R1</i> ; <i>PIK3R3</i> ; <i>SPRY1</i> ; <i>STAT2</i>	7
Axon guidance	<i>CXCL12</i> ; <i>EPHA4</i> ; <i>EPHB6</i> ; <i>SRGAP1</i> ; <i>SRGAP3</i> ; <i>SRGAP2</i>	6
Focal adhesion	<i>FN1</i> ; <i>ITGA10</i> ; <i>ITGB8</i> ; <i>PDGFD</i> ; <i>PIK3R1</i> ; <i>PIK3R3</i>	6
Acute myeloid leukemia	<i>PIK3R1</i> ; <i>PIK3R3</i> ; <i>PML</i> ; <i>RUNX1T1</i> ; <i>ZBTB16</i>	5
Phosphatidylinositol signaling system	<i>IMPA2</i> ; <i>PIK3C2A</i> ; <i>PIK3C3</i> ; <i>PIK3R1</i> ; <i>PIK3R3</i>	5
Apoptosis	<i>CFLAR</i> ; <i>IL1R1</i> ; <i>IRAK4</i> ; <i>PIK3R1</i> ; <i>PIK3R3</i>	5
Toll-like receptor signaling pathway	<i>IRAK4</i> ; <i>MAP2K6</i> ; <i>MAP3K8</i> ; <i>PIK3R1</i> ; <i>PIK3R3</i>	5

**Table 5 Pathways for downregulated genes after expansion in serum-free medium (top 10)**

Pathway	Gene symbol	Count
Cell cycle	<i>BUB1</i> ; <i>BUB1B</i> ; <i>CCNA2</i> ; <i>CCNB1</i> ; <i>CCNB2</i> ; <i>CCNE2</i> ; <i>CDC20</i> ; <i>CDC23</i> ; <i>CDC25A</i> ; <i>CDC25C</i> ; <i>CDC45L</i> ; <i>CDC6</i> ; <i>CDC2</i> ; <i>CDK2</i> ; <i>CDKN2C</i> ; <i>CHEK1</i> ; <i>ESPL1</i> ; <i>MAD2L1</i> ; <i>MCM2</i> ; <i>MCM7</i> ; <i>MCM3</i> ; <i>MCM4</i> ; <i>MCM5</i> ; <i>MCM7</i> ; <i>ORC1L</i> ; <i>PLK1</i> ; <i>PTTG1</i> ; <i>SKP2</i> ; <i>SMAD3</i> ; <i>TFDP1</i> ; <i>TGFB1</i> ; <i>TGFB2</i> ; <i>WEE1</i> ; <i>YWHAH</i> ; <i>YWHAZ</i>	34
Cytokine–cytokine receptor interaction	<i>CCL2</i> ; <i>CCL26</i> ; <i>CXCL1</i> ; <i>CXCL3</i> ; <i>CXCL5</i> ; <i>CXCL6</i> ; <i>TNFSF13B</i> ; <i>EGF</i> ; <i>EGFR</i> ; <i>FLT1</i> ; <i>IL11</i> ; <i>IL1A</i> ; <i>IL1B</i> ; <i>IL6</i> ; <i>IL7R</i> ; <i>IL8</i> ; <i>INHBA</i> ; <i>LIF</i> ; <i>PDGFC</i> ; <i>PF4V1</i> ; <i>CCL14</i> ; <i>TGFB1</i> ; <i>TGFB2</i> ; <i>TNFRSF11B</i> ; <i>VEGFA</i>	25
Focal adhesion	<i>ACTB</i> ; <i>COL4A6</i> ; <i>COL6A1</i> ; <i>EGF</i> ; <i>EGFR</i> ; <i>FLNB</i> ; <i>FLT1</i> ; <i>GRLF1</i> ; <i>ITGA4</i> ; <i>ITGA5</i> ; <i>ITGA6</i> ; <i>ITGB3</i> ; <i>MAPK8</i> ; <i>MYLK</i> ; <i>PAK2</i> ; <i>PDGFC</i> ; <i>PDPK1</i> ; <i>PRKCA</i> ; <i>PTK2</i> ; <i>TLN1</i> ; <i>TNC</i> ; <i>VASP</i> ; <i>VEGFA</i>	23
Regulation of actin cytoskeleton	<i>ACTB</i> ; <i>BDKRB1</i> ; <i>DIAPH3</i> ; <i>EGF</i> ; <i>EGFR</i> ; <i>FGF1</i> ; <i>FGF2</i> ; <i>FGF13</i> ; <i>GRLF1</i> ; <i>IQGAP3</i> ; <i>ITGA4</i> ; <i>ITGA5</i> ; <i>ITGA6</i> ; <i>ITGB3</i> ; <i>MYH9</i> ; <i>MYLK</i> ; <i>NRAS</i> ; <i>PAK2</i> ; <i>PDGFC</i> ; <i>PIPSK1A</i> ; <i>PTK2</i>	21
Mitogen-activated protein kinase signaling pathway	<i>DUSP4</i> ; <i>EGF</i> ; <i>EGFR</i> ; <i>FGF1</i> ; <i>FGF2</i> ; <i>FGF13</i> ; <i>FLNB</i> ; <i>IL1A</i> ; <i>IL1B</i> ; <i>MAPK8</i> ; <i>MAPKAPK2</i> ; <i>NRAS</i> ; <i>PAK2</i> ; <i>PRKACB</i> ; <i>PRKCA</i> ; <i>RPS6KA3</i> ; <i>MAP3K7IP2</i> ; <i>TGFB1</i> ; <i>TGFB2</i>	19
DNA polymerase	<i>FEN1</i> ; <i>MCM2</i> ; <i>MCM7</i> ; <i>MCM3</i> ; <i>MCM4</i> ; <i>MCM5</i> ; <i>MCM7</i> ; <i>POLA1</i> ; <i>POLA2</i> ; <i>POLE2</i> ; <i>PRIM1</i> ; <i>PRIM2</i> ; <i>RFC2</i> ; <i>RFC3</i> ; <i>RFC4</i> ; <i>RFC5</i> ; <i>RNASEH2A</i>	16
Cell adhesion molecules	<i>CD276</i> ; <i>CDH2</i> ; <i>CLDN1</i> ; <i>ITGA4</i> ; <i>ITGA6</i> ; <i>JAM3</i> ; <i>NEGR1</i> ; <i>NEO1</i> ; <i>NRXN3</i> ; <i>PDCD1LG2</i> ; <i>PTPRF</i> ; <i>PVR</i> ; <i>PVRL2</i> ; <i>SDC1</i> ; <i>VCAN</i>	15
Gap junction	<i>CDC2</i> ; <i>EGF</i> ; <i>EGFR</i> ; <i>GNAS</i> ; <i>NRAS</i> ; <i>PDGFC</i> ; <i>PLCB1</i> ; <i>PRKACB</i> ; <i>PRKCA</i> ; <i>TUBA4A</i> ; <i>TUBB2A</i> ; <i>TUBB</i> ; <i>TUBB2C</i> ; <i>TUBB6</i>	14
Pyrimidine metabolism	<i>CTPS</i> ; <i>POLA1</i> ; <i>POLA2</i> ; <i>POLE2</i> ; <i>POLR2D</i> ; <i>POLR3G</i> ; <i>PRIM1</i> ; <i>PRIM2</i> ; <i>RRM1</i> ; <i>RRM2</i> ; <i>TK1</i> ; <i>TYMS</i> ; <i>UCK2</i>	13
Purine metabolism	<i>GART</i> ; <i>PDE7B</i> ; <i>PDE8A</i> ; <i>PFAS</i> ; <i>POLA1</i> ; <i>POLA2</i> ; <i>POLE2</i> ; <i>POLR2D</i> ; <i>POLR3G</i> ; <i>PRIM1</i> ; <i>PRIM2</i> ; <i>RRM1</i> ; <i>RRM2</i>	13

genome and reduced growth rate. The aCGH data did not support a striking increase of CNV in SFM-expanded hUC-MSCs, so we cannot blame genome instability for the downregulation of DNA repair-related genes. Reduced growth might thus be a more reasonable explanation. A reduced growth rate led to fewer DNA replications and less DNA errors. So the requirements for mismatch repair




and nucleotide excision repair were reduced in SFM-expanded hUC-MSCs. Interestingly, we observed at least five histone-related genes upregulated in SFM-expanded hUC-MSCs: *HIST1H2AC*, *HIST1H2BC*, *HIST1H2BD*, *HIST1H2BK*, *HIST1H4H*. However, we have no idea why histone increased their expression level in SFM-expanded hUC-MSCs, and thus this needs to be further studied.

### Real-time PCR validation

To confirm and strengthen the findings derived from the mRNA chip, we selected 12 genes and measured their expression level by real-time PCR. As shown in Figure 6, almost all genes analyzed by real-time PCR showed a similar expression profile in the mRNA chip. Real-time PCR data also indicated that genes involved in the cell cycle pathway (*CCNA2*, *CDC20*, *CDK1*) were downregulated, while *HIST1H2AC* and *HIST1H2BC* were upregulated in SFM-expanded hUC-MSCs.

### Discussion

Attaching and proliferating on plastic is a well-described property of MSCs. Fetal bovine serum provides abundant attachment and growth factors that are essential for MSC maintenance and growth. Some SFMs for MSCs are not free of animal-derived components. They need the flask surface to be coated with substrates isolated from animal or human. These substrates are ill-defined and vary significantly between different batches. When compared with animal-derived materials, xeno-free coating substrates that contain components derived from human might be more dangerous. While a previous study reported that MSCs may proliferate in three-dimensional cultures without serum and coating substance [39], the three-dimensional system is expensive and not suitable for large-scale expansion to clinical application. To improve cell attachment, a plasma surface treatment is used



in *ex vivo* expansion of MSCs. Only in one out of three commercial SFMs provided by different companies in this study can hUC-MSCs attach and propagate well on the plasma-treated surface. Being similar to the bone marrow-derived MSCs cultured in autologous serum [40], hUC-MSCs cultured in SFM require more prolonged exposure to trypsin to dissociate from the plastic surface than hUC-MSCs cultured in SCM. This could be explained, based on the data of transcriptome analysis, by upregulation of many molecules related to cell adhesion (*GPNMB*,

*CXCL12*, *COL21A1*, *ITGBL1*). However, we found that hUC-MSCs cultured in SFM could be detached much easier in collagenase compared with trypsin.

Here, we build a system with a xeno-free, serum-free, chemically defined medium and a chemically treated culture surface to expand hUC-MSCs. Neither animal-derived or human-derived protein, nor ill-defined component is included in our culture system. This is a stable, safe, controllable system and thus is suitable for preparing hUC-MSCs for clinical application. The growth rate of hUC-MSCs in

this system was lower than in SCM, but all hUC-MSCs in this study could propagate for at least seven passages, which means the amount of hUC-MSCs could be amplified more than 2,000 times (about 11 population doublings) before reaching the senescent stage. If the cell number of the primary culture was  $1 \times 10^7$  [22], we could obtain more than  $2 \times 10^{10}$  hUC-MSCs at the seventh passage in SFM, which met the quantity requirement of MSCs for clinical applications.

hUC-MSCs derived from different donors showed a different lifespan in *in vitro* culture. Sometimes, the difference of lifespan between samples was very striking. In the present study, sample 2 maintained proliferative capacities even after 20 passages in SFM. However, sample 4 reached senescence at the 10th passage in SFM. So, we cannot analyze or evaluate SFM for MSCs only in one sample. For fair reproducibility, SFM should be evaluated in MSCs derived from different donors and different tissues.

Considering the close link between genome instability and tumor genesis, whether SFM-expanded MSCs maintain genome stability is also an important safety issue for clinical application. We utilized high-throughput aCGH to evaluate the effect of long-term culture in SFM and in SCM on genomic stability of hUC-MSCs in *in vitro* culture. We found that hUC-MSCs gain copy number changes in culture, no matter whether in SFM or in SCM. This was consistent with the finding in adipose tissue-derived MSCs [15], but differed from the data derived from bone marrow-derived MSCs [33], which might be caused by resolution of different methods. However, our results did not support that hUC-MSCs possess better or worse genome stability in SFM or in SCM.

Tumorigenicity is a most important safety issue when cellular therapies are applied in clinical trials. Many conventional and new technologies provide abundant methods to analyze the genome stability and tumorigenicity. However, Prockop and Keating suggest that 'the most reliable and simplest test is: do the cells senesce in culture? If they do, they are unlikely to produce tumors or malignancies in patients' [41]. Previous research has demonstrated that MSCs are unlikely to undergo malignance transformation after long-term culture in SCM [33]. Yet this research did not answer well whether hUC-MSCs were likely to transform or immortalize in SFM. In this study, all hUC-MSC samples derived from five different donors showed growth arrest and senescence in SFM. Thus, we could conclude that hUC-MSCs derived from our culture system, which consisted of SFM and a chemically treated surface, did not undergo malignant transformation.

SFM-expanded hUC-MSCs showed a clear different gene expression profile compared with hUC-MSCs cultured in SCM based on our microarray data. Cell cycle, mitosis and cell proliferation were downregulated in SFM-expanded hUC-MSCs. We observed a low level of *hTERT*

in SCM-expanded hUC-MSCs, which cannot be found in SFM-expanded hUC-MSCs. Nevertheless, based on the analysis of cell surface marker and multipotency, SFM-expanded hUC-MSCs met the minimal criteria for human MSCs [29]. The co-culture experiment also revealed that SFM-expanded hUC-MSCs maintained their immunosuppressive ability, which is consistent with previous studies [19,20]. The change of biological characteristics that was found in SFM-expanded hUC-MSCs might not influence their future clinical applications.

## Conclusions

We studied biological characteristics and therapeutic potential of hUC-MSCs that were expanded in a serum-free and chemically defined culture. Our results indicated that many growth rate-related biological characteristics of hUC-MSCs were altered in SFM. However, SFM-expanded hUC-MSCs met the basic criteria for human MSCs and also maintained immunosuppressive ability. Besides, SFM expansion did not change the genetic stability of hUC-MSCs. SFM-expanded hUC-MSCs are therefore suitable for clinical application.

## Additional file

**Additional file 1: Figure S1.** Showing quantification of *hTERT* and *RPLP0* mRNA in SFM-expanded hUC-MSCs and HeLa (positive control) by TaqMan based real-time PCR. No expression of *hTERT* was detected in SFM-expanded hUC-MSCs derived from five different donors. HeLa were *hTERT*-positive.

## Abbreviations

aCGH: array-based comparative genomic hybridization; CDK: cyclin-dependent kinase; CNV: copy number variation; hPBMC: human peripheral blood mononuclear cell; hUC-MSC: human umbilical cord mesenchymal stem cell; IFN $\gamma$ : interferon gamma; MSC: mesenchymal stem cell; SCM: serum-containing medium; SFM: serum-free medium.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

YouW carried out the conception and design. YouW and HW drafted the manuscript, carried out the differentiation analysis, bioinformatics analysis and real-time PCR analysis. HW carried out the co-culture experiment, BrdU incorporation analysis, IFN $\gamma$  concentration measurement, and senescence-associated  $\beta$ -galactosidase analysis. ZY performed flow cytometry analysis. YC performed the differentiation analysis. LM, AM, SY, SH, JZ, YZ, WY, YM, TL and YC carried out cell culture. YonW, SW, JL, JH, CL, LL and JX performed the isolation of hUC-MSCs. Z-BH and ZCH conceived the study, and participated in design, provision of study material and data analysis. ZCH participated in manuscript writing. All authors read and approved the final manuscript.

## Acknowledgements

The authors appreciate Dr Zhaojun Zhang (Laboratory of Disease Genomics and Individualized Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China) and Dr Ya Xu (CapitalBio Co.) for their very kind help with bioinformatics analysis. This study was supported by The National Basic Research Program of China (973 Program; 2011CB964802), the National Natural Science Foundation of China (81330015, 31470951) and the Tianjin Research Program of Application Foundation and Advanced Technology (12JCZDJC25000).

#### Author details

<sup>1</sup>State Key Laboratory of Experimental Hematology, National Engineering Research Center of Stem Cells, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Science & Peking Union Medical College, 288 Nanjing Road, 300020 Tianjin, China. <sup>2</sup>National Engineering Research Center of Cell Products/AmCellGene Co. Ltd, 80 Fourth Street in Tianjin Economic and Technological Development Zone Block B3, 300457 Tianjin, China. <sup>3</sup>TEDA Life Science and Technology Research Center, Institute of Hematology, Chinese Academy of Medical Science, 80 Fourth Street in Tianjin Economic and Technological Development Zone Block B4, 300457 Tianjin, China.

Received: 19 February 2014 Revised: 18 November 2014

Accepted: 19 November 2014 Published: 4 December 2014

#### References

- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: **Multilineage potential of adult human mesenchymal stem cells.** *Science* 1999, **284**:143–147.
- Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, Kon E, Maracci M: **Repair of large bone defects with the use of autologous bone marrow stromal cells.** *N Engl J Med* 2001, **344**:385–386.
- Cancedda R, Mastrogiacomo M, Bianchi G, Derubeis A, Muraglia A, Quarto R: **Bone marrow stromal cells and their use in regenerating bone.** *Novartis Found Symp* 2003, **249**:133–143. discussion 143–147, 170–174, 239–241.
- Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, Locatelli F, Fibbe WE: **Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation.** *Blood* 2007, **110**:2764–2767.
- Karlsson H, Samarasinghe S, Ball LM, Sundberg B, Lankester AC, Dazzi F, Uzunel M, Rao K, Veyss P, Le Blanc K, Ringden O, Amrolia PJ: **Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses.** *Blood* 2008, **112**:532–541.
- Le Blanc K, Frassonni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O, Developmental Committee of the European Group for Blood and Marrow Transplantation: **Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.** *Lancet* 2008, **371**:1579–1586.
- Friedenstein AJ, Latzinik NW, Grosheva AG, Gorskaya UF: **Marrow microenvironment transfer by heterotopic transplantation of freshly isolated and cultured cells in porous sponges.** *Exp Hematol* 1982, **10**:217–227.
- Garcia S, Bernad A, Martin MC, Cigudosa JC, Garcia-Castro J, de la Fuente R: **Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells.** *Exp Cell Res* 2010, **316**:1648–1650.
- Spits C, Mateizel I, Geens M, Mertzanidou A, Staessen C, Vandekelde Y, Van der Elst J, Liebaers I, Sermon K: **Recurrent chromosomal abnormalities in human embryonic stem cells.** *Nat Biotechnol* 2008, **26**:1361–1363.
- Lefort N, Feyeux M, Bas C, Feraud O, Bennaceur-Griscelli A, Tachdjian G, Peschanski M, Perrier AL: **Human embryonic stem cells reveal recurrent genomic instability at 20q11.21.** *Nat Biotechnol* 2008, **26**:1364–1366.
- Draper JS, Smith K, Gokhale P, Moore HD, Maltby E, Johnson J, Meisner L, Zwaka TP, Thomson JA, Andrews PW: **Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells.** *Nat Biotechnol* 2004, **22**:53–54.
- Buzzard JJ, Gough NM, Crook JM, Colman A: **Karyotype of human ES cells during extended culture.** *Nat Biotechnol* 2004, **22**:381–382. author reply 382.
- Maitra A, Arking DE, Shivapurkar N, Ikeda M, Stastny V, Kassaei K, Sui G, Cutler DJ, Liu Y, Brimble SN, Noaksson K, Hyllner J, Schulz TC, Zeng X, Freed WJ, Crook J, Abraham S, Colman A, Sartipy P, Matsui S, Carpenter M, Gazdar AF, Rao M, Chakravarti A: **Genomic alterations in cultured human embryonic stem cells.** *Nat Genet* 2005, **37**:1099–1103.
- Narva E, Autio R, Rahkonen N, Kong L, Harrison N, Kitsberg D, Borghese L, Itskovitz-Eldor J, Rasool O, Dvorak P, Hovatta O, Otonkoski T, Tuuri T, Cui W, Brüstle O, Baker D, Maltby E, Moore HD, Benvenisty N, Andrews PW, Yli-Harja O, Lahesmaa R: **High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity.** *Nat Biotechnol* 2010, **28**:371–377.
- Meza-Zepeda LA, Noer A, Dahl JA, Micci F, Myklebost O, Collas P: **High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence.** *J Cell Mol Med* 2008, **12**:553–563.
- Peeters CM, Leijns MJ, Reijman M, van Osch GJ, Bos PK: **Safety of intra-articular cell-therapy with culture-expanded stem cells in humans: a systematic literature review.** *Osteoarthritis Cartilage* 2013, **21**:1465–1473.
- Witzeneder K, Lindenmair A, Gabriel C, Holler K, Theiss D, Redl H, Hennerbichler S: **Human-derived alternatives to fetal bovine serum in cell culture.** *Transfus Med Hemother* 2013, **40**:417–423.
- Jung S, Panchalingam KM, Rosenberg L, Behie LA: **Ex vivo expansion of human mesenchymal stem cells in defined serum-free media.** *Stem Cells Int* 2012, **2012**:123030.
- Chase LG, Lakshmiathy U, Solchaga LA, Rao MS, Vemuri MC: **A novel serum-free medium for the expansion of human mesenchymal stem cells.** *Stem Cell Res Ther* 2010, **1**:8.
- Wu M, Han ZB, Liu JF, Wang YW, Zhang JZ, Li CT, Xin PL, Han ZC, Zhu XP: **Serum-free media and the immunoregulatory properties of mesenchymal stem cells in vivo and in vitro.** *Cell Physiol Biochem* 2014, **33**:569–580.
- Wang Y, Han ZB, Song YP, Han ZC: **Safety of mesenchymal stem cells for clinical application.** *Stem Cells Int* 2012, **2012**:652034.
- Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, Lu YX, Liu D, Chen ZZ, Han ZC: **Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials.** *Haematologica* 2006, **91**:1017–1026.
- Bieche I, Nogues C, Paradis V, Olivi M, Bedossa P, Lidereau R, Vidaud M: **Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay.** *Clin Cancer Res* 2000, **6**:452–459.
- Chen K, Wang D, Du WT, Han ZB, Ren H, Chi Y, Yang SG, Zhu D, Bayard F, Han ZC: **Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism.** *Clin Immunol* 2010, **135**:448–458.
- Wang D, Chen K, Du WT, Han ZB, Ren H, Chi Y, Yang SG, Bayard F, Zhu D, Han ZC: **CD14+ monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells.** *Exp Cell Res* 2010, **316**:2414–2423.
- CapitalBio Corporation. [http://www.capitalbio.com]
- Workman C, Jensen LJ, Jarmer H, Berka R, Gautier L, Nielsen HB, Saxild HH, Nielsen C, Brunak S, Knudsen S: **A new non-linear normalization method for reducing variability in DNA microarray experiments.** *Genome Biol* 2002, **3**:research0048.
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: **Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.** *Genome Biol* 2002, **3**:RESEARCH0034.
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: **Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.** *Cytotherapy* 2006, **8**:315–317.
- Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, Scadden DT, Ma'ayan A, Enikolopov GN, Frenette PS: **Mesenchymal and haematopoietic stem cells form a unique bone marrow niche.** *Nature* 2010, **466**:829–834.
- Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA: **Creation of human tumour cells with defined genetic elements.** *Nature* 1999, **400**:464–468.
- Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelutz AJ: **Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells.** *Nature* 1998, **396**:84–88.
- Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG, Zuffardi O, Locatelli F: **Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms.** *Cancer Res* 2007, **67**:9142–9149.
- Parsch D, Fellenberg J, Brummendorf TH, Eschbeck AM, Richter W: **Telomere length and telomerase activity during expansion and differentiation of human mesenchymal stem cells and chondrocytes.** *J Mol Med (Berl)* 2004, **82**:49–55.
- Nigg EA: **Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle.** *Bioessays* 1995, **17**:471–480.

36. DaFonseca CJ, Shu F, Zhang JJ: **Identification of two residues in MCM5 critical for the assembly of MCM complexes and Stat1-mediated transcription activation in response to IFN-gamma.** *Proc Natl Acad Sci U S A* 2001, **98**:3034–3039.
37. Nakatsuru S, Sudo K, Nakamura Y: **Isolation and mapping of a human gene (MCM2) encoding a product homologous to yeast proteins involved in DNA replication.** *Cytogenet Cell Genet* 1995, **68**:226–230.
38. Tamama K, Fan VH, Griffith LG, Blair HC, Wells A: **Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells.** *Stem Cells* 2006, **24**:686–695.
39. Cardoso TC, Ferrari HF, Garcia AF, Novais JB, Silva-Frade C, Ferrarezi MC, Andrade AL, Gameiro R: **Isolation and characterization of Wharton's jelly-derived multipotent mesenchymal stromal cells obtained from bovine umbilical cord and maintained in a defined serum-free three-dimensional system.** *BMC Biotechnol* 2012, **12**:18.
40. Shahdadfar A, Fronsdal K, Haug T, Reinholt FP, Brinchmann JE: **In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability.** *Stem Cells* 2005, **23**:1357–1366.
41. Prockop DJ, Keating A: **Relearning the lessons of genomic stability of human cells during expansion in culture: implications for clinical research.** *Stem Cells* 2012, **30**:1051–1052.

doi:10.1186/scrt522

**Cite this article as:** Wang *et al.*: Human mesenchymal stem cells possess different biological characteristics but do not change their therapeutic potential when cultured in serum free medium. *Stem Cell Research & Therapy* 2014 **5**:132.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

